Recombinant EphB4-HSA fusion protein + HMA (azacitidine or decitabine)
Current understanding
Recombinant EphB4-HSA is a first-in-class receptor tyrosine kinase-targeting fusion protein (EphB4 extracellular domain fused to human serum albumin) that blocks EphB4/EphrinB2 signaling implicated in leukemic stem cell niche interactions and angiogenesis. It is being evaluated in an early-phase trial (trial-early) combined with azacitidine or decitabine in patients with relapsed/refractory MDS, CMML, or AML who have previously failed an HMA, addressing a major unmet need in the HMA-failure setting. Efficacy and safety data are not yet mature.
Evidence log
Open questions
Related
Contributing findings
Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent
08-jun-2026
novelty 4
per-area 4
introduces